On October 28, 2021 Hexagon Bio reported that (Press release, Hexagon Bio, OCT 28, 2021, View Source;30-september-2021-301410679.html [SID1234592159])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Third quarter 2021

Net sales increased by 15 per cent to 1,077.2 MEUR (939.9). Using fixed exchange rates and a comparable group structure (organic growth), net sales increased by 10 per cent
Adjusted operating earnings (EBIT1) increased by 19 per cent to 296.8 MEUR (250.1
Earnings before taxes, excluding adjustments, amounted to 290.5 MEUR (242.2)
Net earnings, excluding adjustments, amounted to 238.3 MEUR (198.6)
Earnings per share, excluding adjustments, amounted to 0.09 EUR (0.08)
Operating cash flow decreased to 179.6 MEUR (191.2)
For further information, please contact:

Maria Luthström, Head of Sustainability and Investor Relations, Hexagon AB, +46 8 601 26 27, [email protected]

This is information that Hexagon AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on 28 October 2021.

This information was brought to you by Cision View Source

View Source;30-september-2021,c3441913